# Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

> **NCT04941287** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 57 (actual)

## Conditions studied

- Metastatic Distal Bile Duct Adenocarcinoma
- Metastatic Gallbladder Carcinoma
- Metastatic Intrahepatic Cholangiocarcinoma
- Recurrent Distal Bile Duct Adenocarcinoma
- Recurrent Gallbladder Carcinoma
- Recurrent Intrahepatic Cholangiocarcinoma
- Stage IV Distal Bile Duct Cancer AJCC v8
- Stage IV Gallbladder Cancer AJCC v8
- Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Unresectable Liver Carcinoma

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cobimetinib
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Varlilumab

## Key facts

- **NCT ID:** NCT04941287
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-15
- **Primary completion:** 2024-01-02
- **Final completion:** 2026-04-29
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04941287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04941287, "Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04941287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*